Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 416 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (0.9% Sodium chloride) infusion Clear all
Terminated Phase 2 Interventional Results available

Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen

NCT04839965
View directory record Official record
Conditions
COVID-19
Interventions
Ampion, Saline
Biological · Other
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 14, 2026, 4:06 AM EDT
Recruiting Phase 2Phase 3 Interventional

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

NCT06947928
View directory record Official record
Conditions
Advanced Or Metastatic Merkel Cell Carcinoma
Interventions
IFx-Hu2.0, Placebo, Pembrolizumab
Drug
Lead sponsor
TuHURA Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 14, 2026, 4:06 AM EDT
Recruiting Phase 4 Interventional

Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery

NCT07131592
View directory record Official record
Conditions
Drain Output After Breast Reduction Surgery, Breast Reductions
Interventions
IV TXA, Topical TXA, Topical saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

NCT01360840
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
EMD 525797, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
12
States / cities
Pleasant Hill, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery

NCT02953587
View directory record Official record
Conditions
Obesity
Interventions
Oral Glucose Tolerance Test (OGTT), Human Ghrelin, Saline
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 14, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

NCT06599697
View directory record Official record
Conditions
Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy
Interventions
Intravenously administered pooled human immunoglobulin (IVIG)
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Baltimore, Maryland • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 1Phase 2 Interventional

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

NCT04381468
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Pepinemab, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

NCT04459338
View directory record Official record
Conditions
Healthy
Interventions
Exendin-9,39, Saline
Biological · Other
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 14, 2026, 4:06 AM EDT
Active, not recruiting Phase 3 Interventional

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117
View directory record Official record
Conditions
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
Interventions
Oregovomab, Paclitaxel, Carboplatin, Placebo
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Colorado-Oregon Altitude Study

NCT05734716
View directory record Official record
Conditions
Acute Mountain Sickness
Interventions
Erythropoietin, Iron sucrose (Venofer), Sterile Sodium Chloride
Drug
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Leadville, Colorado • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia

NCT02059135
View directory record Official record
Conditions
Preeclampsia
Interventions
Recombinant human antithrombin (ATryn), Normal Saline 0.9%
Biological · Other
Lead sponsor
rEVO Biologics
Industry
Eligibility
16 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Not applicable Interventional Results available

Treatment of Suicidal Ideation With Intravenous Ketamine Infusion

NCT01887990
View directory record Official record
Conditions
Depression, Suicidal Ideation
Interventions
Ketamine, placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Consciousness, Psilocybin, and Well-Being

NCT05592379
View directory record Official record
Conditions
Healthy, Psychedelic Experiences, Sleep
Interventions
Psilocybin, Clonidine, Saline
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Early Phase 1 Interventional Results available

Ketamine Infusion for Social Anxiety Disorder

NCT02083926
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Ketamine, Saline
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of KINE-101 in Healthy Volunteers

NCT07343323
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KINE-101, Placebo
Drug
Lead sponsor
Kine Sciences Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 14, 2026, 4:06 AM EDT
Active, not recruiting Phase 3 Interventional

The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial

NCT02261415
View directory record Official record
Conditions
Cancer, Tumour, Surgery
Interventions
Tranexamic acid (TXA), Normal saline
Drug
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older
Enrollment
1,386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

NCT02367040
View directory record Official record
Conditions
Lymphoma,Non-Hodgkin
Interventions
Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
16
States / cities
West Covina, California • Ashland, Kentucky • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen

NCT02848729
View directory record Official record
Conditions
Pain
Interventions
Oral Acetaminophen, IV Acetaminophen, IV Morphine, Placebo Tablets, Saline
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Tucson, Arizona • Naples, Florida • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

NCT04920786
View directory record Official record
Conditions
Alzheimer Disease
Interventions
TB006, Sterile saline (Placebo)
Drug · Other
Lead sponsor
TrueBinding, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 14, 2026, 4:06 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

NCT03403751
View directory record Official record
Conditions
Acute Kidney Injury, Peritonitis, Necrotizing Soft Tissue Infection
Interventions
Reltecimod 0.5 mg/kg, Placebo
Drug
Lead sponsor
Atox Bio Ltd
Industry
Eligibility
18 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 14, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

NCT07223229
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
EI-001, Placebo
Biological · Other
Lead sponsor
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Huntington Beach, California • Hollywood, Florida • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 4 Interventional Results available

Effect of Valproic Acid Concentration on Photic Response

NCT00609245
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 14, 2026, 4:06 AM EDT
Not listed Phase 2 Interventional

YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation

NCT00876902
View directory record Official record
Conditions
Ischemia Reperfusion Injury
Interventions
recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

NCT02292784
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban, Atosiban, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Weeks to 20 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Park Ridge, Illinois • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 14, 2026, 4:06 AM EDT